重组蛋白转导域-寡聚化域-血凝素融合蛋白抑制慢性粒细胞白血病BaF3-P210细胞小鼠致瘤能力  

Protein transduction domain-oligomerization domain-hemagglutinin fusion proteins inhibit tumorigenicity of chronic myeloid leukemia BaF3-P210 cells in mice

作　　者：季茂胜[1] 黄峥兰[1] 李亚娟[1] 黄世峰[1] 曾建明[1] 刘钉宾[1] 曹唯希[1] 冯文莉[1] 

机构地区：[1]重庆医科大学临床血液学教研室,临床检验诊断学教育部重点实验室,重庆400016

出　　处：《肿瘤》2011年第7期591-595,共5页Tumor

基　　金：国家自然科学基金资助项目(编号:30670901)

摘　　要：目的:探讨重组蛋白转导域-寡聚化域-血凝素(protein transduction domain-oligomerization domain-hemagglutinin,PTD-OD-HA)对慢性粒细胞白血病(chronic myeloid leukemia,CML)BaF3-P210细胞小鼠致瘤能力的影响。方法:将BaF3-P210细胞和经40μmol/L PTD-OD-HA处理48h的BaF3-P210细胞分别经尾静脉注射入BALB/c小鼠体内,观察小鼠一般状况以及生存时间,计数外周血白细胞,外周血和骨髓涂片进行Wright-Giemsa染色,肝、脾和肺等各主要脏器组织进行HE染色,蛋白质印迹法检测小鼠骨髓细胞bcr/abl蛋白的表达。结果:BaF3-P210细胞组和经PTD-OD-HA处理的BaF3-P210细胞组小鼠CML发病率分别为90%(9/10)和80%(8/10),外周血白细胞计数分别为(44.3±4.8)×109/L和(20.6±3.2)×109/L(P<0.05),骨髓细胞中bcr/abl癌蛋白表达量分别为5.13±0.46和1.32±0.29(P<0.05),平均生存期分别为(101.3±6.2)d和(185.4±8.7)d(P<0.05)。Wright-Giemsa染色可见,经PTD-OD-HA处理的BaF3-P210细胞组小鼠骨髓、肝脏和脾脏中的白血病细胞浸润程度比BaF3-P210细胞组下降。结论:经PTD-OD-HA处理后的BaF3-P210细胞在BALB/c小鼠体内的致白血病潜能明显受到抑制。Objective： To investigate the effect of protein transduction domain-oligomerization domain-hemagglutinin （PTD-OD-HA） fusion proteins on tumorigenic ability of chronic myeloid leukemia （CML） BaF3-P210 cells in mice. Methods： The untreated BaF3-P210 cells and BaF3-P210 cells treated with 40 IJmol/L PTD-OD-HA for 48 h were injected into BALB/c mice through the tail vein, respectively. The general status and survival time of mice in each group were observed. The number of peripheral white blood cells （WBCs） was counted. The Wright-Giemsa-stained blood and bone marrow smears were examined. The pathological changes of liver, spleen and lung tissues were observed by HE staining. The expression level of bcr/abl protein in bone marrow cells from mice was determined by Western blotting. Results： The incidence rates of CML in mice in the untreated BaF3-P210 cell group and the PTD-OD- HA-treated BaF3-P210 cell group were 90% （9/10） and 80% （8/10）, respectively; WBCs counts in the two groups were （44.3＋4.8）~109/L and （20.6＋3.2）~109/L （P〈0.05）, respectively; the expression levels of bcr/abl protein in bone marrow cells in the two groups were 5.13＋__0.46 and 1.32＋0.29 （P〈0.05）, respectively. The average survivals in the untreated BaF3-P210 cell group and the PTD-OD-HA-treated BaF3-P210 cell group were （101.3＋6.2） d and （185.4_＋8.7） d （P〈0.05）, respectively. Wright-Giemsa staining showed that the infiltration degree of leukemic cells in bone marrow, liver and spleen waslower in the PTD-OD-HA-treated BaF3-P210 cell group than that in the untreated BaF3-P210 cell group. Conclusion： PTD-OD-HA can inhibit the tumorigenic ability of CML with BaF3-P21 0 cells in BALB/c mice.

关 键 词：白血病 髓样 融合蛋白质类 BCR—ABL 疾病模型 动物 

分 类 号：R733.7[医药卫生—肿瘤]